1313219-06-5

Basic information

• Product Name: N-{3-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-benzyl}-methanesulfonamide
• Synonyms: N-{3-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-benzyl}-methanesulfonamide
• CAS NO: 1313219-06-5
• Molecular Weight: 460.557
• Mol File: 1313219-06-5.mol

Chemical Properties

• CAS DataBase Reference: N-{3-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-benzyl}-methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{3-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-benzyl}-methanesulfonamide(1313219-06-5)
• EPA Substance Registry System: N-{3-[6-(2-Benzyloxy-phenyl)-pyrimidin-4-ylamino]-benzyl}-methanesulfonamide(1313219-06-5)

Safety Data

• Hazardous Substances Data: 1313219-06-5(Hazardous Substances Data)

Upstream product

• 1313219-05-4 N-[3-(6-Chloro-pyrimidin-4-ylamino)-benzyl]-methanesulfonamide 
• 190661-29-1 2-benzyloxyphenylboronic acid 
• 26177-43-5 3-nitrobenzylamine hydrochloride 

Relevant articles and documents

4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY

The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group,W is a group of formula —NH—SO2—R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY

The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula -NH-SO2-R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.